Interpharm Development Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 30-12-2024
- Paid Up Capital ₹ 1.67 Cr
as on 30-12-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 59.50 Cr
as on 30-12-2024
- Revenue %
(FY 2022)
- Profit 61.24%
(FY 2022)
- Ebitda -22.41%
(FY 2022)
- Net Worth -0.28%
(FY 2022)
- Total Assets 51.11%
(FY 2022)
About Interpharm Development
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.67 Cr.
The company currently has active open charges totaling ₹59.50 Cr.
Prerna Garg and Anuj Garg serve as directors at the Company.
- CIN/LLPIN
U24230GJ2005PTC046401
- Company No.
046401
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jul 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Interpharm Development?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prerna Garg  | Director | 04-Oct-2023 | Current |
| Anuj Garg | Director | 01-Dec-2022 | Current |
Financial Performance of Interpharm Development.
Interpharm Development Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 61.24% increase in profit. The company's net worth dipped by a decrease of 0.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Interpharm Development?
Unlock access to Interpharm Development's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Dec 2023 | ₹6.50 Cr | Open |
Hdfc Bank Limited Creation Date: 10 Apr 2023 | ₹6.50 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Mar 2023 | ₹46.50 Cr | Open |
How Many Employees Work at Interpharm Development?
Unlock and access historical data on people associated with Interpharm Development, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Interpharm Development, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Interpharm Development's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
